10 Journal of the National Medical Association, vol. 99, no. 11, pp. 1243–1247, 2007. [95] G. G. Wulf, G. Jahns-Streusel, R. Nobiling et al., “Renin in acute myeloid leukaemia blasts,” British Journal of Haematol- ogy, vol. 100, no. 2, pp. 335–337, 1998. [96] G. G. Wulf, G. Jahns-Streubel, F. Strutz et al., “Paraneoplastic hypokalemia in acute myeloid leukemia: a case of renin activity in AML blast cells,” Annals of Hematology, vol. 73, no. 3, pp. 139–141, 1996. [97] R. P. Pinto, K. K. Wang, H. Khoury, A. D. Schimmer, and M. D. Minden, “Aberrant expression of angiotensin in acute myeloid leukemia,” Blood, vol. 102, p. 2124A, 2004. [98] A. Takeda, C. Goolsby, and N. R. Yaseen, “NUP98-HOXA9 induces long-term proliferation and blocks diﬀerentiation of primary human CD34 hematopoietic cells,” Cancer Research, vol. 66, no. 13, pp. 6628–6637, 2006. [99] I. C. Haznedaro, M. Arici, and Y. B u¨yu¨kas¸ik, “A uni- fying hypothesis for the renin-angiotensin system and hematopoiesis: sticking the pieces together with the JAK- STAT pathway,” Medical Hypotheses, vol. 54, no. 1, pp. 80–83, 2000. [100] M. Sayitoglu, I. C. Haznedarogˇlu, O. Hatirnaz et al., “Eﬀects of imatinib mesylate on Renin-Angiotensin System (RAS) activity during the clinical course of chronic myeloid leukaemia,” Journal of International Medical Research, vol. 37, no. 4, pp. 1018–1028, 2009. [101] S. Verstovsek, H. Kantarjian, R. A. Mesa et al., “Safety and eﬃcacy of INCB018424, a JAK1 and JAK2 inhibitor, in myeloﬁbrosis,” New England Journal of Medicine, vol. 363, no. 12, pp. 1117–1127, 2010. [102] M. M. Vrsalovic, V. Pejsa, T. S. Veic et al., “Bone marrow renin-angiotensin system expression in polycythemia vera and essential thrombocythemia depends on JAK2 mutational status,” Cancer Biology and Therapy, vol. 6, no. 9, pp. 1434– 1436, 2007. [103] K. Savary, A. Michaud, J. Favier, E. Larger, P. Corvol, and J. M. Gasc, “Role of the renin-angiotensin system in primitive erythropoiesis in the chick embryo,” Blood, vol. 105, no. 1, pp. 103–110, 2005. [104] E. T. Zambidis, B. Peault, T. S. Park, F. Bunz, and C. I. Civin, “Hematopoietic diﬀerentiation of human embryonic stem cells progresses through sequential hematoendothelial, primitive, and deﬁnitive stages resembling human yolk sac development,” Blood, vol. 106, no. 3, pp. 860–870, 2005. [105] A. Peters, P. W. Burridge, M. V. Pryzhkova et al., “Challenges and strategies for generating therapeutic patient-speciﬁc hemangioblasts and hematopoietic stem cells from human pluripotent stem cells,” International Journal of Developmen- tal Biology, vol. 54, no. 6-7, pp. 965–990, 2010. [106] C. Hubert, K. Savary, J. M. Gasc, and P. Corvol, “The hematopoietic system: a new niche for the renin-angiotensin system,” Nature Clinical Practice Cardiovascular Medicine, vol. 3, no. 2, pp. 80–85, 2006. [107] S. C. Heﬀelﬁnger, “The renin angiotensin system in the regulation of angiogenesis,” Current Pharmaceutical Design, vol. 13, no. 12, pp. 1215–1229, 2007. [108] F. P. Limbourg and H. Drexler, “Bone marrow stem cells for myocardial infarction: eﬀector or mediator?” Circulation Research, vol. 96, no. 1, pp. 6–8, 2005. [109] R. Ross, “Atherosclerosis-an inﬂammatory disease,” The New England Journal of Medicine, vol. 340, pp. 115–126, 1999. [110] S. M. Schwartz, “Smooth muscle migration in atherosclerosis and restenosis,” Journal of Clinical Investigation, vol. 100, no. 11, pp. S87–S89, 1997. Cardiology Research and Practice [111] C. Bauters and J. M. Isner, “The biology of restenosis,” Progress in Cardiovascular Diseases, vol. 40, no. 2, pp. 107– 116, 1997. [112] P. Libby, D. Schwartz, E. Brogi, H. Tanaka, and S. K. Clinton, “A cascade model for restenosis: a special case of atherosclerosis progression,” Circulation, vol. 86, no. 6, supplement, pp. III47–III52, 1992. [113] P. Carmeliet, L. Moons, J. M. Stassen et al., “Vascular wound healing and neointima formation induced by perivascular electric injury in mice,” American Journal of Pathology, vol. 150, no. 2, pp. 761–776, 1997. [114] T. Asahara, H. Masuda, T. Takahashi et al., “Bone mar- row origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization,” Circulation Research, vol. 85, no. 3, pp. 221–228, 1999. [115] T. Asahara, T. Murohara, A. Sullivan et al., “Isolation of putative progenitor endothelial cells for angiogenesis,” Science, vol. 275, no. 5302, pp. 964–967, 1997. [116] K. Ito, A. Hirao, F. Arai et al., “Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells,” Nature Medicine, vol. 12, no. 4, pp. 446–451, 2006. [117] W. Strawn, R. Richmond, and C. Ferrario, “A new under- standing of atherosclerosis: the bone marrow response-to- lipid hypothesis,” in Heart Disease: Pathogenesis, Diagnosis and Treatment, pp. 183–188, 3rd World Congress on Heart Disease, Washington, DC, USA, 2003. [118] W. B. Strawn and C. M. Ferrario, “Angiotensin II AT receptor blockade normalizes CD11b(+) monocyte production in bone marrow of hypercholesterolemic monkeys,” Atheroscle- rosis, vol. 196, no. 2, pp. 624–632, 2008. [119] D. Fukuda and M. Sata, “The renin-angiotensin system: a potential modulator of endothelial progenitor cells,” Hyper- tension Research, vol. 30, no. 11, pp. 1017–1018, 2007. [120] L. A. Cassis, D. L. Rateri, H. Lu, and A. Daugherty, “Bone marrow transplantation reveals that recipient AT1a receptors are required to initiate angiotensin II-induced atherosclerosis and aneurysms,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 2, pp. 380–386, 2007. [121] Y. Tsubakimoto, H. Yamada, H. Yokoi et al., “Bone marrow angiotensin AT1 receptor regulates diﬀerentiation of mono- cyte lineage progenitors from hematopoietic stem cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 10, pp. 1529–1536, 2009. [122] T. Yamada, T. Kondo, Y. Numaguchi et al., “Angiotensin II receptor blocker inhibits neointimal hyperplasia through regulation of smooth muscle-like progenitor cells,” Arte- riosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 11, pp. 2363–2369, 2007. [123] H. Lu, D. L. Rateri, D. L. Feldman et al., “Renin inhibi- tion reduces hypercholesterolemia-induced atherosclerosis in mice,” Journal of Clinical Investigation, vol. 118, no. 3, pp. 984–993, 2008. [124] H. Kato, J. Ishida, K. Nagano et al., “Deterioration of atherosclerosis in mice lacking angiotensin II type 1A recep- tor in bone marrow-derived cells,” Laboratory Investigation, vol. 88, no. 7, pp. 731–739, 2008. [125] D. Fukuda, S. Enomoto, R. Nagai, and M. Sata, “Inhibi- tion of renin-angiotensin system attenuates periadventitial inﬂammation and reduces atherosclerotic lesion formation,” Biomedicine and Pharmacotherapy, vol. 63, no. 10, pp. 754– 761, 2009.